Letter to the EditorEffects of a nicotinic agonist on the Brief Psychiatric Rating Scale five-factor subscale model in schizophrenia
Section snippets
Acknowledgements
This work was supported by Autism Speaks grant #9699 (ASL) and by NIH grants R01DA14241, R01MH077681 (MRP), and R25MH071584, T32MH1427 (ASL). The funding sources had no role in the design, analysis, or interpretation of the data.
Conflict of interest
WRK is a co-inventor on a University of Florida patent for DMXB-A. The other authors declare no conflicts of interest.
Contributors
ASL designed the study, performed data analysis, and wrote the manuscript. AO, RWB, WRK, and RF performed data analysis and contributed to writing the manuscript. MRP designed the study and contributed to writing the manuscript.
References (10)
- et al.
Modulation of aggressive behavior in mice by nicotinic receptor subtypes
Biochem. Pharmacol.
(2015) - et al.
Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: a translational meta-analysis of rodent and human studies
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
(2017) - et al.
Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study
Eur. Neuropsychopharmacol.
(2016) Alpha7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia
Annu. Rev. Med.
(2014)- et al.
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Am. J. Psychiatry
(2008)
There are more references available in the full text version of this article.
Cited by (0)
© 2017 Elsevier B.V. All rights reserved.